莱卡尼马布:韩国痴呆症协会的适当使用建议
Kee Hyung Park1, Geon Ha Kim2, Chi-Hun Kim3
1Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Dementia and neurocognitive disorders
|November 8, 2024
概括
在韩国,Lecanemab (Leqembi®) 为早期阿尔茨海默病提供了一种新的治疗方法. 这些指导方针详细介绍了患者选择,监测粉样蛋白相关成像异常 (ARIA),以及有效使用的安全预防措施.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 粉样β斑块是阿尔茨海默病的一个关键病理标志.
- 早期干预对于管理AD的认知衰退至关重要.
研究的目的:
- 为韩国适当使用lecanemab提供临床建议.
- 为了指导医疗保健专业人员在患者选择,管理和监测lecanemab.
- 为了确保这种抗粉样蛋白治疗的安全有效的应用.
主要方法:
- 韩国痴呆症协会制定临床指南.
- 确定患者的资格标准,包括粉样蛋白生物标志物的确认.
- 制定管理前测试 (例如,阿波利波蛋白E基因定型) 和磁共振成像 (MRI) 监测的协议.
- 给药程序的概述和不良事件的管理,如输液相关反应和ARIA.
主要成果:
- 莱卡内马布推给患有轻度认知障碍 (MCI) 或因AD而导致轻度痴呆症的患者,具有阳性粉样蛋白生物标志物.
- 禁忌包括严重的过敏和无法接受MRI.
- 为预测ARIA风险,建议使用Apolipoprotein E基因型鉴定,在治疗期间定期进行MRI监测.
- 与输液相关的反应是常见的不良事件,需要管理.
- 由于出血风险,建议在与抗凝剂或组织等离子素激活剂同时使用时谨慎使用.
结论:
- 这些建议有助于在韩国适合和安全地使用lecanemab治疗早期阿尔茨海默病.
- 对患者适应性,风险因素和监测的全面评估至关重要.
- 遵守指南有助于获得最佳的治疗结果和患者安全.
相关概念视频
01:30Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:24Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222